Xencor (XNCR) Q2 Revenue Jumps 82%

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP revenue of $43.6 million exceeded analyst estimates by $21.0 million and Revenue (GAAP) increased by about 82% from the prior year, mainly reflecting milestone and non-cash royalty payments from its partners. Net loss narrowed to $(0.41) per share (GAAP), much better than the $(0.72) expected, helped by increases in revenue and lower administrative expenses. Management stated it expects enough cash to support operations and key clinical programs into 2028. The quarter’s results reflected significant financial outperformance and clinical progress in oncology and autoimmune disease pipelines. Source: Analyst estimates for the quarter provided by FactSet. Xencor develops antibody-based therapeutics that use its XmAb platform, a technology to modify proteins known as antibodies to boost their effectiveness in treating cancers and autoimmune diseases. Its XmAb proteins can be engineered to enhance cytotoxicity (the ability to kill target cells), prolong drug half-life in the body, and combine multiple drug functions in a single molecule.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool